Welcome to our dedicated page for The Cooper Companies news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on The Cooper Companies stock.
The Cooper Companies, Inc. (NYSE: COO) is a global medical device company specializing in improving quality of life through innovative products and services. Headquartered in San Ramon, CA, Cooper operates through two main business units: CooperVision and CooperSurgical.CooperVision is a leader in the contact lens industry, offering a diverse range of high-quality contact lenses, including spherical, multifocal, toric, and specialty lenses. With brands like Proclear, Biofinity, MyDay, and Clariti, CooperVision commands roughly one-fourth of the US contact lens market. The company is committed to providing excellent practitioner support, ensuring that both users and professionals benefit from their cutting-edge solutions.
CooperSurgical, founded in 1990, focuses on women's health and fertility, offering market-leading products and treatment options. The division supplies clinicians with over 600 medical devices and treatment solutions related to reproductive care, fertility, and women's health. Notably, CooperSurgical owns Paragard, the only hormone-free IUD available in the US, holding a 17% share of the US IUD market. Additionally, CooperSurgical has the largest medical device coverage for the entire IVF cycle.
With a workforce of over 15,000 employees and products available in more than 130 countries, CooperCompanies is dedicated to delivering shareholder value while enhancing the lives of individuals globally. The company continues to innovate and expand, recently achieving record annual revenues and strong earnings. Noteworthy advancements include a four-for-one stock split set to become effective on February 16, 2024, and partnerships like that with Fulgent Genetics to offer exclusive newborn genetic screening panels through Cord Blood Registry.
Cooper's fiscal year 2023 showcased significant milestones, including double-digit organic growth in their fertility segment and strong performance in contact lenses. As they move into fiscal year 2024, Cooper remains focused on their strategic objectives: gaining market share, driving profitability, and launching innovative products and services.
For more information, please visit CooperCompanies.
CooperCompanies (NYSE: COO) will participate in the Wells Fargo Healthcare Conference on September 7, 2022, at 1:20 PM ET. President and CEO Al White will represent the company in this session. Interested parties can access a live webcast through the investor relations website. A replay will also be available post-event. Based in San Ramon, California, CooperCompanies operates globally with over 12,000 employees and offers a wide range of products through its divisions, CooperVision and CooperSurgical, serving over 100 countries.
CooperCompanies (NYSE: COO) has appointed Nicholas Khadder as its new general counsel and corporate secretary, effective immediately. Khadder brings extensive legal experience, having previously served as general counsel at Standard BioTools Inc. from June 2016 to July 2022 and held several senior roles at Amyris, Inc. and other companies. He holds a Juris Doctor from Berkeley Law. This leadership change is expected to enhance the company's legal strategy and governance.
CooperCompanies (NYSE: COO) will announce its third quarter 2022 financial results on August 31, 2022, at 4:15 PM ET. A conference call will follow at 5:00 PM ET to discuss the results and other corporate developments. Participants can register for the call through a provided link and listen to a simultaneous webcast available on their website. Cooper, headquartered in San Ramon, CA, operates through CooperVision and CooperSurgical, employing over 12,000 people and selling products in more than 100 countries.
CooperCompanies (NYSE: COO) declared a semi-annual dividend of 3 cents per share, payable on August 11, 2022, to stockholders of record on July 27, 2022. This move aligns with the company’s board-approved strategy to distribute annual dividends. CooperCompanies operates through CooperVision and CooperSurgical, focusing on vision care and women's health products, respectively. The company is headquartered in San Ramon, CA, and employs over 12,000 people globally, with sales in more than 100 countries.
CooperCompanies (NYSE: COO) reported a 15% year-over-year revenue increase to $829.8 million for its fiscal second quarter ending April 30, 2022. CooperVision revenue rose 6% to $553.8 million, while CooperSurgical surged 40% to $276.0 million. GAAP diluted EPS was $2.55, up $0.19, while non-GAAP diluted EPS fell 4% to $3.24. Operating margin decreased to 16% from 20% due to currency effects. The company updated fiscal 2022 revenue guidance to $3,280 - $3,312 million.
CooperVision has appointed Alex Wilkes as President of the Americas, effective June 14, 2022. Wilkes, with over a decade of experience in the eye care industry, previously served as Senior VP and GM of Pearle Vision at Luxottica. He will oversee growth strategies for the U.S., Canada, and Latin America. Mark Harty, EVP and Chief Commercial Officer, emphasized Wilkes' success in driving growth and market strategies. Wilkes expressed enthusiasm about joining CooperVision, aligning with its values and innovative product direction.
CooperCompanies (NYSE: COO) will participate in the Jefferies Healthcare Conference on June 9, 2022, at 1:00 PM ET. Al White, the President and CEO, will represent the company during this session.
The event can be accessed via CooperCompanies’ website, with a replay available 48 hours post-event. CooperCompanies is a global medical device firm operating through CooperVision and CooperSurgical, focusing on vision care and women's health products. Headquartered in San Ramon, CA, the company employs over 12,000 people and sells products in more than 100 countries.
CooperCompanies (NYSE: COO) has published its 2021 ESG Highlights Report, detailing ESG progress relevant to stakeholders. Highlights include a 100% score on the Human Rights Campaign’s Corporate Equality Index, gender parity on the Board, and 35% ethnic diversity in the workforce. Cooper became a participant in the UN Global Compact initiative.
CooperCompanies (NYSE: COO) announced that it and Cook Medical received a second request from the FTC regarding the acquisition of Cook Medical’s Reproductive Health business. This request, part of the HSR Act's regulatory process, extends the waiting period until compliance is achieved. The companies are collaborating with the FTC and anticipate closing the deal by the end of 2022.
Cooper operates two business units: CooperVision and CooperSurgical, focusing on medical devices and fertility solutions.
EssilorLuxottica and CooperCompanies have finalized their joint venture agreement for SightGlass Vision, focusing on innovative myopia management technologies. This collaboration aims to commercialize Diffusion Optics Technology™, which can potentially slow myopia progression in children by scattering light to reduce retinal contrast. With myopia affecting 2.6 billion globally, the partnership aims to enhance awareness and access to solutions. The lenses are not yet approved for sale in the U.S., marking an important step in addressing the rising myopia prevalence projected to impact half of the global population by 2050.
FAQ
What is the current stock price of The Cooper Companies (COO)?
What is the market cap of The Cooper Companies (COO)?
What does The Cooper Companies, Inc. specialize in?
Where is The Cooper Companies, Inc. headquartered?
What are some of CooperVision's popular contact lens brands?
What makes CooperSurgical unique in the women's health market?
How many employees does The Cooper Companies, Inc. have?
What recent financial achievements has CooperCompanies reported?
In how many countries are CooperCompanies’ products available?
What recent partnerships has CooperSurgical announced?
What are CooperCompanies' strategic objectives for fiscal year 2024?
Where can I find more information about The Cooper Companies, Inc.?
